In that same way today, some companies are intent on not only not letting the machines take over and oust the humans, but are making sure that they use technological advancement--whether it be AI or technology in general--to always improve and benefit humankind rather than looking for ways to displace it.
AI hasn’t skipped over the pharma industry. In fact, life science companies have been developing AI and machine-learning algorithms for years. These programs are usually used to sort through mountains of information, whether it’s for researchers in clinical trials or healthcare providers treating patients.
Bringing a new therapy to market typically exceeds $1 billion dollars and takes 10 years. How can pharma companies safely and successfully accelerate the drug development timeline and reduce cost? Artificial intelligence (AI) enabled technologies are showing potential to increase efficiencies by improving both site and patient recruitment in clinical trials.
Two San Luis Obispo County hospitals are using artificial intelligence to detect strokes, a move that makes treatment more efficient and could even save lives, according to a local physician.
This algorithm leverages AI to automatically search for the presence of a suspected abdominal aortic aneurysm (AAA) from any computed tomography angiography (CTA) from any scanner in any institution in a hospital network that uses the company’s platform.
Tenet Health Central Coast is now using new technology in conjunction with an application that will help health workers diagnose and respond more quickly to patients suffering from a stroke.
Hidden biases, reduced privacy, and over-reliance on non-transparent, decision-making black boxes can cut against democratic values, potentially putting our civil rights at risk. This means that the effective and equitable use of AI will be based on solving inherent ethical, safety, data privacy and cybersecurity challenges.
A Chattanooga-based research team has found a cellphone app — also launched in Chattanooga — that uses artificial intelligence reduced the diagnosis time for the deadliest type of stroke by 44% compared to cases in which the app wasn't used.
One way to strike fear into patients and cardiologists alike is to merely mention the abdominal aortic aneurysm (AAA), an event that claims more than 10,000 lives per year in the U.S. alone. That death count might fall substantially going forward thanks to the U.S. FDA’s award of a 510(k) for the AAA algorithm by Viz.ai Inc., a new algorithm which may help clinicians address imminent rupture quickly enough to save the lives of thousands of American patients each year.
In its latest step toward that goal, Viz has secured the FDA’s clearance for yet another of its AI algorithms. This one, according to a Tuesday announcement, is designed to look for signs of an abdominal aortic aneurysm (AAA), in which the section of the aorta that runs through the stomach begins to bulge or swell.
The companies on this year’s list—which kicks off the second decade of Fierce Medtech’s Fierce 15—are setting the bar even higher. | Since its humble beginnings back in 2012, the Fierce 15 has made a point of spotlighting the most exciting startups in medtech—those not only challenging the limits of both the tech and healthcare industries but also making real progress toward their lofty goals. The companies on this year’s list—which kicks off the second decade of Fierce Medtech’s Fierce 15—are setting the bar even higher.
Viz.ai has unveiled plans to use its Viz RECRUIT platform for optimising the enrolment of participants in the NIH-funded Pulmonary Embolism-Thrombus Removal with Catheter-Directed Thrombolysis (PE-TRACT) clinical trial.